280 related articles for article (PubMed ID: 30231510)
1. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies.
Dogliotti I; Drandi D; Genuardi E; Ferrero S
J Clin Med; 2018 Sep; 7(9):. PubMed ID: 30231510
[TBL] [Abstract][Full Text] [Related]
2. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
Assanto GM; Del Giudice I; Della Starza I; Soscia R; Cavalli M; Cola M; Bellomarino V; Di Trani M; Guarini A; Foà R
Front Oncol; 2023; 13():1152467. PubMed ID: 36998457
[TBL] [Abstract][Full Text] [Related]
3. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
4. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
Drandi D; Ferrero S; Ladetto M
Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
[TBL] [Abstract][Full Text] [Related]
5. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
6. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia.
Della Starza I; De Novi LA; Elia L; Bellomarino V; Beldinanzi M; Soscia R; Cardinali D; Chiaretti S; Guarini A; Foà R
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672325
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
8. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
Colmenares R; Álvarez N; Barrio S; Martínez-López J; Ayala R
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267616
[TBL] [Abstract][Full Text] [Related]
9. [Latest advances in minimal residual disease evaluation in B-cell lymphoproliferative disease].
Wang Y; Wen FQ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Jun; 22(6):667-671. PubMed ID: 32571470
[TBL] [Abstract][Full Text] [Related]
10. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
11. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsies and minimal residual disease in lymphoid malignancies.
Bou Zerdan M; Kassab J; Saba L; Haroun E; Bou Zerdan M; Allam S; Nasr L; Macaron W; Mammadli M; Abou Moussa S; Chaulagain CP
Front Oncol; 2023; 13():1173701. PubMed ID: 37228488
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R; Ayala R; Martínez-López J
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
[TBL] [Abstract][Full Text] [Related]
15. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.
Takamatsu H
J Clin Med; 2017 Sep; 6(10):. PubMed ID: 28946710
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?
Hauwel M; Matthes T
Swiss Med Wkly; 2014 Jan; 144():w13907. PubMed ID: 24452390
[TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
[TBL] [Abstract][Full Text] [Related]
19. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
20. The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of
Guerrini F; Paolicchi M; Ghio F; Ciabatti E; Grassi S; Salehzadeh S; Ercolano G; Metelli MR; Del Re M; Iovino L; Petrini I; Carulli G; Cecconi N; Rousseau M; Cervetti G; Galimberti S
Front Pharmacol; 2016; 7():363. PubMed ID: 27790140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]